Risk factors for ECEs
MVA . | Risk for ECEs, HR (95% CI) . | P value . |
---|---|---|
Age, y | ||
> 60 (vs younger) | 1.36 (0.74-2.50) | .315 |
HTN | ||
Yes (vs no) | 2.01 (1.06-3.80) | .030 |
DLP | ||
Yes (vs no) | 2.42 (1.20-4.86) | .012 |
Diabetes mellitus | ||
Yes (vs no) | 0.49 (0.16-1.44) | .197 |
Previous cardiac pathology | ||
Yes (vs no) | 1.39 (0.68-2.85) | .355 |
Disease status before allo-HCT | ||
Active disease (vs complete remission) | 1.70 (0.77-3.75) | .182 |
Conditioning regimen | ||
MAC regimen containing CY (vs others) | 0.85 (0.30-2.42) | .773 |
GVHD prophylaxis | ||
PTCY-based prophylaxis (vs other) | 2.86 (1.32-6.21) | .007 |
Donor type | ||
Haploidentical donors (vs HLA-matched and MMUD) | 1.16 (0.57-2.39) | .674 |
Grade 3-4 aGVHD | ||
Time-dependent variable | 2.19 (0.88-5.43) | .088 |
MVA . | Risk for ECEs, HR (95% CI) . | P value . |
---|---|---|
Age, y | ||
> 60 (vs younger) | 1.36 (0.74-2.50) | .315 |
HTN | ||
Yes (vs no) | 2.01 (1.06-3.80) | .030 |
DLP | ||
Yes (vs no) | 2.42 (1.20-4.86) | .012 |
Diabetes mellitus | ||
Yes (vs no) | 0.49 (0.16-1.44) | .197 |
Previous cardiac pathology | ||
Yes (vs no) | 1.39 (0.68-2.85) | .355 |
Disease status before allo-HCT | ||
Active disease (vs complete remission) | 1.70 (0.77-3.75) | .182 |
Conditioning regimen | ||
MAC regimen containing CY (vs others) | 0.85 (0.30-2.42) | .773 |
GVHD prophylaxis | ||
PTCY-based prophylaxis (vs other) | 2.86 (1.32-6.21) | .007 |
Donor type | ||
Haploidentical donors (vs HLA-matched and MMUD) | 1.16 (0.57-2.39) | .674 |
Grade 3-4 aGVHD | ||
Time-dependent variable | 2.19 (0.88-5.43) | .088 |
Variables included in the multivariate model were selected based on results reported in supplemental Table 1 (univariate regression analysis) and if considered clinically relevant for cardiac toxicity according to previous related publications. Posttransplant follow-up has been censored at 100 days. No event diagnosed after day +100 has been accounted for this analysis.
MMUD, mismatched unrelated donor.